Alector (ALEC) Set to Announce Quarterly Earnings on Thursday

Alector (NASDAQ:ALEC) will likely be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.23) per share and revenue of $2.19 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Alector (NASDAQ:ALEC) last released its earnings results on Thursday, August 6th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.02. Alector had a negative return on equity of 531.03% and a negative net margin of 850.13%. The firm had revenue of $3.32 million during the quarter, compared to analyst estimates of $1.71 million. On average, analysts expect Alector to post ($0.47) EPS for the current fiscal year and ($0.78) EPS for the next fiscal year.

Alector Stock Up 3.3%

Shares of NASDAQ:ALEC opened at $2.22 on Tuesday. The stock’s 50-day moving average price is $2.08 and its two-hundred day moving average price is $2.03. The company has a current ratio of 5.26, a quick ratio of 5.26 and a debt-to-equity ratio of 0.80. Alector has a 12-month low of $1.09 and a 12-month high of $2.76. The firm has a market cap of $247.88 million, a price-to-earnings ratio of -2.02 and a beta of 0.62.

Insider Transactions at Alector

In related news, CEO Arnon Rosenthal sold 72,606 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $2.66, for a total value of $193,131.96. Following the transaction, the chief executive officer owned 2,294,600 shares in the company, valued at approximately $6,103,636. This trade represents a 3.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Neil Berkley sold 29,251 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $2.66, for a total transaction of $77,807.66. Following the completion of the transaction, the chief financial officer owned 350,649 shares in the company, valued at $932,726.34. The trade was a 7.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 111,303 shares of company stock worth $295,633. Company insiders own 8.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ALEC shares. HC Wainwright upped their price objective on shares of Alector from $5.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, October 14th. Weiss Ratings upgraded shares of Alector from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. UBS Group restated a “neutral” rating and issued a $1.50 target price on shares of Alector in a report on Tuesday, October 6th. Finally, Morgan Stanley upped their price target on shares of Alector from $2.00 to $3.00 and gave the stock an “underweight” rating in a research report on Tuesday, October 6th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.62.

Alector Company Profile

Alector, Inc (NASDAQ: ALEC) is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s research platform, known as immuno-neurology, is designed to use the body’s immune system to protect or restore the brain’s ability to maintain healthy neural connections.

Alector’s investigational pipeline has included antibody-based treatments for conditions such as frontotemporal dementia and Alzheimer’s disease. Its programs have targeted biological pathways associated with neurodegeneration, including progranulin and TREM2.